Toward individualized evidence-based medicine: Five "N of 1" trials of methylphenidate in geriatric patients

Citation
Ihm. Jansen et al., Toward individualized evidence-based medicine: Five "N of 1" trials of methylphenidate in geriatric patients, J AM GER SO, 49(4), 2001, pp. 474-476
Citations number
5
Categorie Soggetti
Public Health & Health Care Science","General & Internal Medicine
Journal title
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
ISSN journal
00028614 → ACNP
Volume
49
Issue
4
Year of publication
2001
Pages
474 - 476
Database
ISI
SICI code
0002-8614(200104)49:4<474:TIEMF">2.0.ZU;2-W
Abstract
OBJECTIVES: To investigate the efficacy of methylphenidate in depressed or apathetic geriatric patients. DESIGN: Five "N of 1" trials (individual cross-over, double-blinded, random ized trials). SETTING: Department of Geriatrics, University Medical Center, Nijmegen, and two nursing homes in Nijmegen, the Netherlands. PARTICIPANTS: Patients suffered from depression due to a general medical co ndition (n = 2); depression resistant to antidepressive drugs (n = 1), chro nic apathy due to mild and moderate severe dementia (n = 2). INTERVENTION: Methylphenidate (5 mg bid) and placebo (both for two subseque nt days) in 5 weeks of randomized treatment blocks. MEASUREMENTS: Montgomery Asberg Depression Rating Scale (MADRS), Apathy Eva luation Scale (AES)-clinician, the AES-informant, Barthel index and a semiq uantitative checklist of adverse effects. RESULTS: Among the three depressed patients, two showed significant improve ment on the MADRS (P =.089 and P =.001; alpha = 0.10), one patient's apathy showed significant improvement on AES-clinician and -informant (P =.077 an d P =.086). One apathetic patient's trial was stopped be cause AES could no t be completed. None of the patients showed significant changes in the Bart hel index. No side effects developed. CONCLUSION: "N of 1" trials are useful in evaluating efficacy of methylphen idate in depressed or apathetic geriatric patients. Single-patient trials c an be a useful tool in pharmacotherapeutic decision-making in frail older s ubjects.